MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 29 03 2019
revised: 25 07 2019
accepted: 09 09 2019
pubmed: 15 9 2019
medline: 27 5 2020
entrez: 15 9 2019
Statut: ppublish

Résumé

The NuRD chromatin remodeling and deacetylation complex, which includes MTA1, MBD3, CHD4, and HDAC1 among other components, is of importance for development and cancer progression. The oncogenic mucin 1 (MUC1) C-terminal subunit (MUC1-C) protein activates EZH2 and BMI1 in the epigenetic reprogramming of triple-negative breast cancer (TNBC). However, there is no known link between MUC1-C and chromatin remodeling complexes. Here, we showed that MUC1-C binds directly to the MYC HLH-LZ domain and identified a previously unrecognized MUC1-C→MYC pathway that regulates the NuRD complex. MUC1-C/MYC complexes selectively activated the

Identifiants

pubmed: 31519689
pii: 0008-5472.CAN-19-1034
doi: 10.1158/0008-5472.CAN-19-1034
pmc: PMC6881519
mid: NIHMS1050524
doi:

Substances chimiques

Biomarkers, Tumor 0
Estrogen Receptor alpha 0
MUC1 protein, human 0
Mucin-1 0
Mi-2 Nucleosome Remodeling and Deacetylase Complex EC 3.5.1.98

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

5711-5722

Subventions

Organisme : NCI NIH HHS
ID : R21 CA229716
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA232979
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA097098
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA233084
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166480
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

EMBO J. 2006 Mar 22;25(6):1231-41
pubmed: 16511565
Cancer Res. 2014 Mar 1;74(5):1484-94
pubmed: 24413532
Cancer Metastasis Rev. 2014 Dec;33(4):879-89
pubmed: 25344802
Sci Rep. 2017 Aug 7;7(1):7481
pubmed: 28785086
PLoS One. 2015 Aug 12;10(8):e0135156
pubmed: 26267657
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3384-9
pubmed: 19211792
Oncol Lett. 2017 Aug;14(2):1247-1264
pubmed: 28789340
Mol Cancer Ther. 2019 Oct;18(10):1744-1754
pubmed: 31308076
Mol Cell. 2006 Jan 20;21(2):295-305
pubmed: 16427018
Cell. 2008 Mar 21;132(6):958-70
pubmed: 18358809
J Biol Chem. 2012 Mar 9;287(11):8598-612
pubmed: 22270359
Biomed Pharmacother. 2017 Nov;95:956-964
pubmed: 28915537
EMBO Rep. 2010 Sep;11(9):691-7
pubmed: 20651739
Oncogene. 2008 Mar 27;27(14):1971-80
pubmed: 17922032
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11651-6
pubmed: 16087863
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
Nat Rev Mol Cell Biol. 2017 Jul;18(7):407-422
pubmed: 28512350
FEBS J. 2017 Dec;284(24):4216-4232
pubmed: 29063705
EMBO J. 2012 Feb 1;31(3):593-605
pubmed: 22139358
Oncogene. 2013 Feb 28;32(9):1073-81
pubmed: 22580612
Mol Cell. 2018 Aug 16;71(4):554-566.e7
pubmed: 30078722
Mol Cell. 2018 Jul 5;71(1):56-72.e4
pubmed: 30008319
Cancer Res. 2016 Mar 15;76(6):1538-48
pubmed: 26833129
Cancer Genet Cytogenet. 2007 Oct 15;178(2):94-103
pubmed: 17954264
Oncogene. 2011 May 12;30(19):2230-41
pubmed: 21258411
Cell. 2006 Dec 1;127(5):1041-55
pubmed: 17129787
Cell Mol Life Sci. 2018 Jul;75(14):2537-2555
pubmed: 29691590
Oncogene. 2014 Mar 27;33(13):1680-9
pubmed: 23584475
Oncogene. 2016 Oct 13;35(41):5400-5411
pubmed: 27041579
Mol Cancer Res. 2015 Mar;13(3):449-60
pubmed: 25368430
Nature. 2000 Nov 16;408(6810):377-81
pubmed: 11099047
Mol Cancer Ther. 2011 May;10(5):806-16
pubmed: 21421804
Cancer Res. 2009 Sep 1;69(17):7013-21
pubmed: 19706766
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13968-73
pubmed: 16172399
Nat Commun. 2018 Mar 9;9(1):1024
pubmed: 29523784
Nat Rev Cancer. 2011 Jul 07;11(8):588-96
pubmed: 21734722
Mol Cancer Res. 2016 Dec;14(12):1266-1276
pubmed: 27658423
Cancer Metastasis Rev. 2014 Dec;33(4):993-1000
pubmed: 25332144
Nat Rev Mol Cell Biol. 2016 Mar;17(3):183-93
pubmed: 26883003
Cancer Cell. 2017 May 8;31(5):653-668.e7
pubmed: 28486105
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122
pubmed: 28302417
J Biol Chem. 2012 Mar 23;287(13):10703-13
pubmed: 22318732
Oncogene. 2018 Apr;37(16):2079-2088
pubmed: 29379165
Nat Cell Biol. 2007 Feb;9(2):201-9
pubmed: 17187062
Nat Cell Biol. 2006 Mar;8(3):285-92
pubmed: 16462733
Nat Cell Biol. 2001 Jan;3(1):30-7
pubmed: 11146623
Cell Stem Cell. 2014 Jul 3;15(1):102-10
pubmed: 24835571

Auteurs

Tsuyoshi Hata (T)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Hasan Rajabi (H)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Hidekazu Takahashi (H)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yota Yasumizu (Y)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Wei Li (W)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Caining Jin (C)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Mark D Long (MD)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Qiang Hu (Q)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Song Liu (S)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Atsushi Fushimi (A)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Nami Yamashita (N)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Ling Kui (L)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Deli Hong (D)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Masaaki Yamamoto (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Masaaki Miyo (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Masayuki Hiraki (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Takahiro Maeda (T)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yozo Suzuki (Y)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Mehmet K Samur (MK)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Donald Kufe (D)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. donald_kufe@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH